Climb Bio Q3 net loss $8.9M; cash $217.9M through 2027; FDA IND cleared for SLE trial

Climb Bio, Inc.

2024-Q3 EPS reported -$1.57

Net loss $8.9M for Q3 2024 vs $4.0M Q3 2023; R&D expenses $6.2M, G&A $5.5M.
Cash $217.9M as of Sep 30, 2024; expected to fund operations through 2027.
FDA cleared IND for budoprutug in SLE; Phase 1b trial planned H1 2025.
Appointed Doug Williams as Chair of Board; Gary Hao as VP of CMC.
Phase 1b pMN data showed 60% complete remission; Phase 2 ITP trial planned H1 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.